Last reviewed · How we verify

low dose clonidine HCl sustained release — Competitive Intelligence Brief

low dose clonidine HCl sustained release (low dose clonidine HCl sustained release) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central alpha-2 adrenergic agonist. Area: Cardiovascular.

phase 3 Central alpha-2 adrenergic agonist Alpha-2 adrenergic receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

low dose clonidine HCl sustained release (low dose clonidine HCl sustained release) — Addrenex Pharmaceuticals, Inc.. Clonidine HCl works by stimulating alpha-2 adrenergic receptors in the brain, which decreases sympathetic nervous system activity and lowers blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
low dose clonidine HCl sustained release TARGET low dose clonidine HCl sustained release Addrenex Pharmaceuticals, Inc. phase 3 Central alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
Escitalopram+Mirtazapine Escitalopram+Mirtazapine Ministry of Health & Welfare, Korea marketed Antidepressant combination (SSRI + NaSSA) Serotonin transporter (SERT), norepinephrine transporter (NET), alpha-2 adrenergic receptors, histamine H1 receptors
dexmedetomidine 1 µg/kg IV dexmedetomidine 1 µg/kg IV American University of Beirut Medical Center marketed Alpha-2 adrenergic agonist Alpha-2 adrenergic receptor
High-dose dexmedetomidine High-dose dexmedetomidine Tang-Du Hospital marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
mometasone furoate + Oxymetazoline mometasone furoate + Oxymetazoline Guangzhou Women and Children's Medical Center marketed Intranasal corticosteroid + nasal decongestant combination Glucocorticoid receptor (mometasone); alpha-2 adrenergic receptor (oxymetazoline)
dexmedetomidine (IN) dexmedetomidine (IN) Azienda Ospedaliera di Padova marketed Alpha-2 adrenergic receptor agonist Alpha-2 adrenergic receptor
Norepinephrine (Levophed) Norepinephrine (Levophed) University of Louisville marketed Catecholamine; sympathomimetic amine Alpha-1 adrenergic receptor; alpha-2 adrenergic receptor; beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central alpha-2 adrenergic agonist class)

  1. Addrenex Pharmaceuticals, Inc. · 1 drug in this class
  2. Heart Care Foundation · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). low dose clonidine HCl sustained release — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-clonidine-hcl-sustained-release. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: